Global Burden and Treatment Trajectiories in Italian Patients With Fabry Disease

Overview

GROUND study is an Italian, multicenter retrospective longitudinal cohort study with a cross-sectional phase with the aim to quantify the severe clinical burden in terms of severe and fatal outcomes and extension of clinical impairment in the Italian Fabry Disease patients' population

Full Title of Study: “Global Burden and Treatment Trajectiories in Italian Patients With Fabry Disease: a Retrospective, Longitudinal and Cross-sectional Study”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: June 30, 2022

Interventions

  • Other: FD patients
    • Patients with Fabry disease diagnosis

Arms, Groups and Cohorts

  • FD patients

Clinical Trial Outcome Measures

Primary Measures

  • Occurrence of severe and fatal clinical outcomes
    • Time Frame: Baseline
    • Occurrence of severe and fatal clinical outcomes derived by event-free survival from birth to last follow-up or cross-sectional visit;
  • Comprehensive burden
    • Time Frame: Baseline
    • Comprehensive burden intended as a measure of extension of clinical impairment assessed by median Mainz Severity Score Index (MSSI) at last follow-up or cross-sectional visit.

Secondary Measures

  • Percentage of patients with disease progression
    • Time Frame: From the first available FASTEX score to baseline
    • Percentage of patients with disease progression measured by FAbry STabilization indEX and defined as a change >20% from the first available FASTEX score to the last follow-up and in the last 2 years until the last follow-up and 2 years before the last follow-up or cross-sectional visit (or when available within 3-1 years before last follow-up)
  • Percentage of patients with disease activity
    • Time Frame: Baseline
    • Percentage of patients with disease activity assessed by the occurrence rate of clinically significant events from diagnosis to last follow-up or cross-sectional visit.
  • Brief pain inventory score
    • Time Frame: Baseline
    • Uses simple numeric rating scales from 0 (no pain) to 10 (severe pain)
  • Pittsburgh Sleep Quality index
    • Time Frame: Baseline
    • Seven component scores are derived, each scored 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to produce a global score (range 0 to 21). Higher scores indicate worse sleep quality.
  • Hamilton depression scale
    • Time Frame: Baseline
    • It contains 17 items. A score of 0-7 is considered to be normal while a score of 20 or higher (indicating at least moderate severity)
  • HAQ-disability index
    • Time Frame: Baseline
    • There are 8 sections: dressing, arising, eating, walking, hygiene, reach, grip, and activities. There are 2 or 3 questions for each section. Scoring within each section is from 0 (without any difficulty) to 3 (unable to do).The 8 scores of the 8 sections are summed and divided by 8.
  • SF-36
    • Time Frame: Baseline
    • Covers eight health domains: physical functioning (10 items), bodily pain (2 items), role limitations due to physical health problems (4 items), role limitations due to personal or emotional problems (4 items), emotional well-being (5 items), social functioning (2 items), energy/fatigue (4 items), and general health perceptions (5 items). Scores for each domain range from 0 to 100, with a higher score defining a more favorable health state.
  • Time from first manifestation to diagnosis
    • Time Frame: Baseline
    • Time from first manifestation to diagnosis
  • Patients prescribed to different treatments
    • Time Frame: Baseline
    • Percentage of patients prescribed to different treatment among naïve and switchers groups; determinants of untreated, treated discontinue, treated persisting status.

Participating in This Clinical Trial

Inclusion Criteria

1. Adult patients living or deceased of either sex (age ≥18 years) with a documented FD diagnosis in the last 10 years from the beginning of the study. 2. Patients with at least 3 years of follow-up or early occurrence of severe/fatal outcomes. Also, adult patients who were lost by their care provider or physician and cannot be traced, but for which it is possible to retrieve data for at least 3 years before the last available follow-up visit or from diagnosis to the occurrence of severe/fatal outcomes if earlier, can be included. 3. Written informed consent to undergo in the cross-sectional protocol clinical visit and to retrospectively collect genetic/clinical data. In case of deceased or untraceable patients, the written informed consent is not required to collect retrospective clinical data (excluding genetic data). Exclusion Criteria:

  • Not applicable

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Chiesi Italia
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Antonio Pisani, MD, Principal Investigator, Università degli Studi di Napoli “Federico II” NAPOLI
    • Federico Pieruzzi, MD, Principal Investigator, Ospedale San Gerardo MONZA
    • Renzo Mignani, MD, Principal Investigator, AUSL della Romagna – Ospedale Infermi RIMINI
    • Elena Verrecchia, MD, Principal Investigator, Fondazione Policlinico Universitario “Gemelli” IRCCS ROMA
    • Davide Noto, MD, Principal Investigator, A.O.U. Policlinico “Giaccone” PALERMO
    • Antonino Tuttolomondo, MD, Principal Investigator, A.O.U. Policlinico “Giaccone” PALERMO
    • Maurizio Pieroni, MD, Principal Investigator, AUSL Toscana Sud-Est – Ospedale San Donato AREZZO
    • Iacopo Olivotto, MD, Principal Investigator, A.O.U. Careggi FIRENZE

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.